Sporanox
Friday, December 31st, 2004On May 9, 2001. The Food and Drug Administration (FDA) issued a
Public Health Advisory to announce significant safety-related updates
to the labeling of Sporanox products and Lamisil tablets. Sporanox
and Lamisil are used to treat nail (onychomycosis), skin and other
systemic fungal infections.
Potential Heart Damage
The FDA believes there is real risk of developing congestive heart
failure (CHF) associated with the use of Sporanox. Both Sporanox and
Lamisil have been associated with serious liver problems resulting in
liver failure, transplantation and even death.
Results of recent studies of Sporanox showed that the drug can weaken
the force of the heart muscle’s contractions. This condition,
(more…)